Target intelligence / Profile preview

Vacuolating cytotoxin A p55 domain (VacA p55)

Target
VacA p55
Molecular classification
Bacterial toxin, Pore-forming toxin, Autotransporter protein
01

Overview

Vacuolating cytotoxin A (VacA) is a potent protein toxin secreted by Helicobacter pylori, a bacterium strongly linked to the development of peptic ulcers and gastric adenocarcinoma (UniProt P55981). The mature 88 kDa toxin is composed of two main domains: the N-terminal p33 domain and the C-terminal p55 domain (PubMed: 10490605). The p55 domain is essential for the toxin's ability to bind to the surface of host gastric epithelial cells, interacting with various receptors such as receptor-like protein tyrosine phosphatase beta (RPTPβ) and sphingomyelin (PubMed: 15941011). Following binding and internalization, VacA forms anion-selective channels in endosomal and mitochondrial membranes, leading to massive vacuolation, mitochondrial damage, and programmed cell death (PubMed: 22491015). Furthermore, VacA exerts immunomodulatory effects by inhibiting T-cell proliferation and activation, which facilitates chronic bacterial persistence (PubMed: 11274168). Given its critical role in H. pylori virulence, the p55 domain is a primary target for therapeutic interventions, including neutralizing antibodies and small-molecule inhibitors designed to block toxin attachment and subsequent cellular damage (PubMed: 25605869).

Other names
p55 subunitVacA p55Vacuolating cytotoxin p55VacA binding domain
02

Mechanism of action

Inhibition of toxin binding to host cell receptors and prevention of toxin oligomerization.

03

Biological functions

Cell vacuolationPore formationApoptosis inductionMitochondrial dysfunctionImmune response suppression
04

Disease associations

InfectionGastric cancerPeptic ulcer diseaseGastritis
05

Safety considerations

High allelic diversity of VacA across different H. pylori strainsTargeting host-bacterial interactions without disrupting commensal floraDelivery challenges in the acidic gastric environment
06

Interacting drugs

Epigallocatechin gallate (EGCG)

3 more in the full profile.

07

Biomarkers

VacA antibody titersVacA genotype (s-region/m-region/i-region)Gastric mucosal vacuolation

Beyond the preview

Go deeper on Vacuolating cytotoxin A p55 domain (VacA p55).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vacuolating cytotoxin A p55 domain (VacA p55).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call